MedTrace Logo

AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)

NCT05578430 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2022-12-15

No results posted yet for this study

Summary

This is a Phase 2, open-label, single-arm study of neoadjuvant immune-checkpoint blockade therapy (AK104) combining with TACE for resectable hepatocellular carcinoma. The purpose is to investigate the efficacy and safety of this therapeutic regimen to reduce the risk of postoperative recurrence in resectable HCC patients with a high risk of recurrence.

Conditions

  • Resectable Hepatocellular Carcinoma

Interventions

DRUG

Cadonilimab

10mg/kg by intravenous infusions every 3 weeks

PROCEDURE

TACE

TACE will be performed per institutional standard of care.

PROCEDURE

Surgery

Surgery will be performed per institutional standard of care.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2025-01-01
Completion
2025-01-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05578430 on ClinicalTrials.gov